Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Total Non-Current Liabilities (2016 - 2018)

Assembly Biosciences (ASMB) has 4 years of Total Non-Current Liabilities data on record, last reported at $38.9 million in Q4 2018.

  • For Q4 2018, Total Non-Current Liabilities fell 8.84% year-over-year to $38.9 million; the TTM value through Dec 2018 reached $38.9 million, down 8.84%, while the annual FY2018 figure was $38.9 million, 8.84% down from the prior year.
  • Total Non-Current Liabilities reached $38.9 million in Q4 2018 per ASMB's latest filing, roughly flat from $38.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $55.4 million in Q1 2017 and bottomed at $11.1 million in Q4 2016.
  • Average Total Non-Current Liabilities over 4 years is $29.7 million, with a median of $38.9 million recorded in 2018.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 377.93% in 2017, then decreased 26.49% in 2018.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $11.6 million in 2015, then dropped by 4.14% to $11.1 million in 2016, then surged by 283.93% to $42.7 million in 2017, then decreased by 8.84% to $38.9 million in 2018.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $38.9 million in Q4 2018, $38.9 million in Q3 2018, and $40.2 million in Q2 2018.